Shots:

• The P-III PINETREE study; enrolling 584 participants, evaluates Veklury IV to reduce the hospitalization rate or all-cause death among non-hospitalized COVID-19 patients at high risk for disease progression
• Participants receiving Veklury showed 87% reduction in risk for the composite 1EP of COVID-19-related hospitalization or all-cause death by Day 28 and an 81% reduction in the risk for the composite 2EP of COVID-19-related medical visits due to COVID-19 or all-cause death by Day 28 vs. PBO
• The subgroup analyses showed high efficacy for patients regardless of underlying medical conditions associated with a higher risk of severe COVID-19 vs. PBO

Ref: Gilead | Image: Gilead